-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, pharmaceutical industry policies have been introduced, consistent evaluation, China's accession to ICH, MAH implementation, drug clinical trial data verification and other accelerated industry survival of the fittest;
the reform of medical policy, the development of China's pharmaceutical industry is entering the fast track of norms.
the context of the rise of "healthy China" as a national strategy, China is undergoing a transformation from a "medical power" to a "medical power".
biopharmaceutical industry, as one of china's seven strategic emerging industries, is becoming a new engine of China's economic development.
through policy regulation, investment of supporting resources and improvement of institutional mechanism construction, China's biopharmaceutical industry has transitioned from "technological backwardness" to "following the international pace", in which the development of innovative drugs is particularly rapid.
has emerged a number of innovative biopharmaceutical companies, such as Baiji Shenzhou, Xinda Bio, Junshi Bio, and independent research and development of innovative drugs were approved for market.
to sustain rapid growth, more top talent will be needed and the overall level of employees will be improved.
to provide innovative pharmaceutical practitioners with a free and smooth exchange platform, Sina Pharmaceuticals launched a special "New Zhihui" online live knowledge sharing platform, will focus on drug research and development in the target discovery, new technology development and application, process development and verification, drug clinical trial design and other hot topics, through strategy and case sharing, directly hit the confusion in research and development production.
course highlights: 1, keep up with the trend, share the development and application of new technologies; 2, dry goods, focus on case sharing and method analysis; 3, pay tribute to innovation, pay tribute to medical people; 4, the course is open, everyone can become a product manager, your valuable suggestions for live content is our enhanced ability, excellent you can apply to become a course instructor.
Monday, September 14th, the 6th lesson of "New Zhihui" weighs in, and Dr. Ren Zhihua, Director of Translational Medicine Department of Meijie Translational Medicine Research (Suzhou) Co., Ltd., will share with you the "Focus on Tumor Immunotherapy - Translational Medicine Research Strategy for Biomarkers" and look forward to your participation.
Share themes: Focus on the transformational medicine research strategy of tumor immunotherapy- biomarkers 1, the current situation and development prospects of tumor immunotherapy; Director of Translational Medicine Live Time: September 14, 2020 19:30-20:30 Meijie Translational Medicine Research (Suzhou) Co., Ltd. Director of Translational Medicine Dr. Ren Zhihua graduated from Qingdao Medical College with a bachelor's degree in medical examination, and later obtained a ph.D. in medical genetics from Shanghai Jiaoxuan University School of Medicine, and went to the United States in 2005 to work as a postdoctoral fellow in the Department of Neurology of U Chicago, RUSH Medical Center and UMDNJ. He focuses on neuroimmunity and neural stem cell research.
In 2012, Dr. Ren joined the Suzhou Ark Biopharmaceutical Research and Development Center of the Beijing Concord Medical College of the Chinese Academy of Medical Sciences as Deputy Director, during which he presided over the implementation of major research projects at the national level, including the Ministry of Science and Technology," the "12th Five-Year Plan" major new drug creation project and the Wei planning commission's special project for the public welfare industry, and accumulated rich experience in stem cell translation medicine research and research on childhood birth defects.
is currently the Director of the Department of Translational Medicine in Meijie (Suzhou), responsible for translational medicine and pharmaceutical science and technology cooperation, scientific research, academic conference lectures and other work.
: This course is free and open, scan the QR code below to add Sina Medicine Live Assistant, register.
(Note: Name and Company)